Akers Biosciences Inc (AKER):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Akers Biosciences Inc (AKER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3429
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRON, PIFA PLUSS PF4, tri-cholesterol, PIFA chlamydia, PIFA dengue fever, PIFA malaria, PIFA syphilis, PIFA heparin, and breath ketone. ABI provides testing platform technologies, which include micro particle catalyzed biosensor, particle immune-filtration assay, rapid enzymatic assay, rapid blood cell separation, and synthetic macrocycle complex. The company serves medical clinicians, individuals, corporations, and law enforcement agencies, health professionals. ABI is headquartered in West Deptford, New Jersey, the US.

Akers Biosciences Inc (AKER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Akers Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Akers Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 8
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Akers Biosciences Raises Funds in Private Placement of Shares upon Exercise of Warrants 10
Akers Biosciences Raises USD2.1 Million in Private Placement of Shares upon Exercise of Warrants 11
Akers Biosciences Completes Public Offering Of Shares For US$15 Million 12
Akers Biosciences Inc – Key Competitors 13
Akers Biosciences Inc – Key Employees 14
Akers Biosciences Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Joint Venture 15
Recent Developments 16
Financial Announcements 16
Aug 14, 2018: Akers Biosciences announces Q2 and H1 2018 earnings 16
Jul 13, 2018: Akers Biosciences Announces Q1 2018 Earnings 24
Apr 03, 2018: Akers Biosciences Reports Earnings for Fiscal Year 2017 31
Nov 15, 2017: Akers Biosciences Announces Q3 2017 Earnings 36
Aug 15, 2017: Akers Biosciences: Financial Results for the Six Months Ended June 30, 2017 45
Aug 03, 2017: Akers Biosciences Announces Second Quarter Trading Update 47
Corporate Communications 48
Jun 29, 2018: Akers Biosciences Requests Temporary Suspension of Trading on London Stock Exchange 48
May 29, 2018: Akers Biosciences Announces Board Change 49
May 25, 2018: Akers Biosciences Receives Notice of Delinquent Form 10-Q Filing from Nasdaq 50
Apr 26, 2018: Akers Biosciences: Directorate Change 51
Aug 08, 2017: Akers Biosciences Announces Board Changes 52
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Akers Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Akers Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 8
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Akers Biosciences Raises Funds in Private Placement of Shares upon Exercise of Warrants 10
Akers Biosciences Raises USD2.1 Million in Private Placement of Shares upon Exercise of Warrants 11
Akers Biosciences Completes Public Offering Of Shares For US$15 Million 12
Akers Biosciences Inc, Key Competitors 13
Akers Biosciences Inc, Key Employees 14
Akers Biosciences Inc, Subsidiaries 15
Akers Biosciences Inc, Joint Venture 15

List of Figures
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Akers Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Akers Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 8

★海外企業調査レポート[Akers Biosciences Inc (AKER):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Vanguard Group Inc:企業の戦略的SWOT分析
    The Vanguard Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Feilo Sylvania Europe Ltd:企業の戦略的SWOT分析
    Feilo Sylvania Europe Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • CureMeta LLC-製薬・医療分野:企業M&A・提携分析
    Summary CureMeta LLC (CureMeta) is a biotechnology company that concentrates on the development of immunology therapeutics for cancers. The company advances novel antibody drug conjugates targeting pluripotent stem cells. Its pipeline product comprises Bstrongximab-ADC. CureMeta develops the antibod …
  • Cost Plus Inc:企業の戦略的SWOT分析
    Cost Plus Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • India Glycols Ltd (INDIAGLYCO):企業の財務・戦略的SWOT分析
    India Glycols Ltd (INDIAGLYCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hunt’s Foodservice Ltd:企業の戦略・SWOT・財務情報
    Hunt's Foodservice Ltd - Strategy, SWOT and Corporate Finance Report Summary Hunt's Foodservice Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • EQT Corp (EQT):企業の財務・戦略的SWOT分析
    EQT Corp (EQT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Recurrent Energy LLC:電力:M&Aディール及び事業提携情報
    Summary Recurrent Energy LLC (Recurrent Energy), a subsidiary of Canadian Solar Inc. is a mainstream clean energy company that operates a portfolio of solar energy projects and generates electricity. The company develops and operates a portfolio of utility scale power projects. It has more than 4 GW …
  • Alexza Pharmaceuticals Inc:企業の戦略的SWOT分析
    Alexza Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Aohata Corporation:戦略・SWOT・企業財務分析
    Aohata Corporation - Strategy, SWOT and Corporate Finance Report Summary Aohata Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Florida Power & Light Co:発電所・企業SWOT分析
    Florida Power & Light Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Hetero Drugs Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Hetero Drugs Ltd (Hetero) is a manufacturer of active pharmaceutical ingredients, intermediate chemicals and finished dosages. The company specializes in process chemistry, API manufacturing, formulation development, manufacturing and commercialization of bio-generics, and also offers custom …
  • Thor Mining Plc (THR):企業の財務・戦略的SWOT分析
    Summary Thor Mining Plc (Thor Mining) is a mining and mineral exploration and development company. The company carries out acquisition, exploration and develops gold, tungsten and molybdenum properties. Its projects include Molyhil Tungsten and Molybdenum, Spring Hill Gold, Dundas Gold project, and …
  • Ivy Cosmetics Corporation:企業の戦略・SWOT・財務分析
    Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report Summary Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • TMX Group Limited (X):企業の財務・戦略的SWOT分析
    TMX Group Limited (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • HiQ International AB (HIQ):企業の財務・戦略的SWOT分析
    Summary HiQ International AB (HiQ International) is a technology and communication company that offers management consultancy services. The company offers communications solutions, development of software, and business-critical IT systems. It provides services in the areas of telecom media, gaming a …
  • Multan Electric Power Company:発電所・企業SWOT分析
    Multan Electric Power Company – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Nyrstar NV:企業の戦略・SWOT・財務情報
    Nyrstar NV - Strategy, SWOT and Corporate Finance Report Summary Nyrstar NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Corizon Health Inc:企業の戦略的SWOT分析
    Corizon Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Atlas Copco AB:企業の戦略・SWOT・財務情報
    Atlas Copco AB - Strategy, SWOT and Corporate Finance Report Summary Atlas Copco AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆